It’s a great pleasure for me to be in SIOG in October in Montreal. It was a very big opportunity for me to exchange, to learn about geriatric oncology and to present also two of my studies. The first one was about breast cancer in elderly women – clinical, pathologic and prognostic features. It was a retrospective study, about 45 patients above the age of 70 diagnosed with breast cancer, from January 2014 to December 2018. All patients were treated in the Department of Medical Oncology of Mohamed Taher Maamouri Hospital in Tunisia.

45 patients were aged about 65 and over, the average age was 71 years. The most patients had stage 2, about 46.3%, and 76.7% of patients were luminal A. However, 1.7% were luminal B and only 1.2% were human epidermal growth factor receptor 2 positive type. The triple negative was about 14.9%.

In 37% of cases patients had performed neoadjuvant chemotherapy and adjuvant chemotherapy was performed in 29.6% of patients. The most common treatment was hormonal therapy, it was administered to 83.2% of patients. Trastuzumab also was administered to 3.6% of patients. Overall survival and progression free survival at five [??] years were about 85.3% and 90.6% respectively.

So this was the result of the first study which I have presented at SIOG. It was the first study in my country, in Tunisia, about elderly patients. It was a monocentric study but actually currently we are proposing a multicentric study to have a clinical or molecular profile of elderly patients in Tunisia.